60 Degrees Pharma Announces Closing of $1.043 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Rhea-AI Summary

60 Degrees Pharmaceuticals (NASDAQ: SXTP) has closed its previously announced registered direct offering, raising approximately $1.043 million in gross proceeds. The offering included 1,021,549 shares of common stock at $1.021 per share, priced at-the-market under Nasdaq rules.

In a concurrent private placement, the company issued unregistered short-term warrants to purchase up to 2,043,098 shares of common stock at an exercise price of $0.771 per share. These warrants are exercisable upon issuance and will expire after 24 months.

H.C. Wainwright & Co. served as the exclusive placement agent. The company plans to use the net proceeds for working capital and general corporate purposes. The offering was conducted under a shelf registration statement that became effective on July 18, 2024.

Insights

Financial Analyst

This $1.043 million capital raise through a registered direct offering reveals concerning signals about 60 Degrees Pharmaceuticals' financial position and market perception. The offering price of $1.021 per share, coupled with warrants exercisable at $0.771, represents a significant discount to market value and suggests challenging fundraising conditions.

Several critical aspects warrant attention: First, the inclusion of warrants for twice the number of shares being sold (2,043,098 warrants vs 1,021,549 shares) indicates a sweetener was needed to attract investors. The warrant exercise price, set 24.5% below the offering price, points to potential future dilution concerns.

The relatively modest size of the raise - just over $1 million - may only provide runway for a pharmaceutical company, where development costs typically run into millions monthly. This could signal either immediate working capital needs or difficulties securing larger institutional investment. The "at-market" pricing mechanism and involvement of H.C. Wainwright as placement agent suggests a tactical approach to raising necessary capital while minimizing market impact.

For existing shareholders, this financing structure presents significant dilution risk, both immediate and potential future dilution if warrants are exercised. The short 24-month warrant term indicates the company expects to reach meaningful milestones within this timeframe that could support a higher valuation, but also creates a relatively narrow window for value creation.

WASHINGTON, Jan. 30, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of an aggregate of 1,021,549 shares of its common stock at a purchase price of $1.021 per share. In addition, in a concurrent private placement, the Company issued unregistered short-term warrants to purchase up to an aggregate of 2,043,098 shares of common stock. The short-term warrants have an exercise price of $0.771 per share, are exercisable upon issuance and will expire twenty-four months following the date of issuance.

H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.

The aggregate gross proceeds to the Company from the offering were approximately $1.043 million, before deducting the placement agent fees and other offering expenses payable by the Company. The Company currently intends to use the net proceeds from the offering for working capital and other general corporate purposes.

The shares of common stock (but not the short-term warrants issued in the private placement or the shares of common stock underlying such short-term warrants) were offered by the Company pursuant to a “shelf” registration statement on Form S-3 (File No. 333-280796) filed with the Securities and Exchange Commission (“SEC”) on July 12, 2024 and became effective on July 18, 2024. The registered direct offering of the shares of common stock were made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. The prospectus supplement and the accompanying prospectus relating to the shares of common stock being offered in the registered direct offering have been filed with the SEC and is available at the SEC's website at www.sec.gov. Electronic copies of the prospectus supplement and the accompanying prospectus relating to the registered direct offering may also be obtained by contacting H.C. Wainwright & Co. at 430 Park Avenue, 3rd Floor, New York, NY 10022, by telephone at (212) 856-5711 or e-mail at placements@hcwco.com.

The short-term warrants described above were issued in a concurrent private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and Regulation D promulgated thereunder and, along with the shares of common stock underlying the short-term warrants, have not been registered under the Securities Act, or applicable state securities laws. Accordingly, the short-term warrants and underlying shares of common stock may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

About 60 Degrees Pharmaceuticals, Inc.

60 Degrees Pharmaceuticals, Inc., founded in 2010, specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases that affect the lives of millions of people. 60 Degrees Pharmaceuticals, Inc. achieved approval by the U.S. Food and Drug Administration (“FDA”) of its lead product, ARAKODA® (tafenoquine), for malaria prevention, in 2018. 60 Degrees Pharmaceuticals, Inc. also collaborates with prominent research organizations in the U.S., Australia, and Singapore. The 60 Degrees Pharmaceuticals, Inc. mission has been supported through in-kind funding from the U.S. Department of Defense and private institutional investors including Knight Therapeutics Inc., a Canadian-based pan-American specialty pharmaceutical company. 60 Degrees Pharmaceuticals, Inc. is headquartered in Washington D.C., with a majority-owned subsidiary in Australia. Learn more at www.60degreespharma.com. The statements contained herein may include prospects, statements of future expectations and other forward-looking statements that are based on management’s current views and assumptions and involve known and unknown risks and uncertainties. Actual results, performance or events may differ materially from those expressed or implied in such forward-looking statements.

Cautionary Note Regarding Forward-Looking Statements

This press release may contain “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect the current view about future events. When used in this press release, the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan,” or the negative of these terms and similar expressions, as they relate to us or our management, identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: the use of proceeds from the offering; there is substantial doubt as to our ability to continue on a going-concern basis; we might not be eligible for Australian government research and development tax rebates; if we are not able to successfully develop, obtain FDA approval for, and provide for the commercialization of non-malaria prevention indications for tafenoquine (ARAKODA® or other regimen) or Celgosivir in a timely manner, we may not be able to expand our business operations; we may not be able to successfully conduct planned clinical trials or patient recruitment in our trials might be slow or negligible; and we have no manufacturing capacity which puts us at risk of lengthy and costly delays of bringing our products to market. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (“SEC”), including the information contained in our Annual Report on Form 10-K filed with the SEC on April 1, 2024, and our subsequent SEC filings, as well as marked and other conditions. Investors and security holders are urged to read these documents free of charge on the SEC’s website at www.sec.gov. As a result of these matters, changes in facts, assumptions not being realized or other circumstances, the Company’s actual results may differ materially from the expected results discussed in the forward-looking statements contained in this press release. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, except as required by law.

Media Contact:
Sheila A. Burke
SheilaBurke-consultant@60degreespharma.com
(484) 667-6330

Investor Contact:
Patrick Gaynes
patrickgaynes@60degreespharma.com
(310) 989-5666

FAQ

How much did 60 Degrees Pharmaceuticals (SXTP) raise in its January 2025 offering?

60 Degrees Pharmaceuticals raised approximately $1.043 million in gross proceeds through a registered direct offering of common stock.

What was the share price for SXTP's January 2025 registered direct offering?

The shares were priced at $1.021 per share in the at-the-market offering.

How many warrants did SXTP issue in the concurrent private placement?

SXTP issued warrants to purchase up to 2,043,098 shares of common stock at an exercise price of $0.771 per share.

What is the exercise price and expiration of SXTP's January 2025 warrants?

The warrants have an exercise price of $0.771 per share and will expire 24 months after issuance.

How will SXTP use the proceeds from its January 2025 offering?

The company intends to use the net proceeds for working capital and other general corporate purposes.